Miki Kiyota

Moriguchi, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

IKZF1 and KRAS Mutated B-cell Acute Lymphoblastic Leukemia with Pseudo-Chédiak-Higashi Granules.

IKZF1 and KRAS Mutated B-cell Acute Lymphoblastic Leukemia with Pseudo-Chédiak-Higashi Granules.

Journal: Internal medicine (Tokyo, Japan)

Published: October 08, 2025

The Emergence of Subclones Following Initial Chemotherapy in Mixed Phenotype Acute Leukemia.

The Emergence of Subclones Following Initial Chemotherapy in Mixed Phenotype Acute Leukemia.

Journal: Cureus

Published: July 02, 2025

Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum.

Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum.

Journal: Leukemia research reports

Published: July 05, 2023

Negative impact of immunoparesis in response to anti-SARS-CoV-2 mRNA vaccination of patients with multiple myeloma.

Negative impact of immunoparesis in response to anti-SARS-CoV-2 mRNA vaccination of patients with multiple myeloma.

Journal: International journal of hematology

Published: July 03, 2023

Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma Forum.

Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma Forum.

Journal: International journal of hematology

Published: April 04, 2023

Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma.

Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma.

Journal: Leukemia & lymphoma

Published: February 11, 2022

Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study.

Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study.

Journal: International journal of hematology

Published: October 01, 2021

Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients.

Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients.

Journal: Cancer reports (Hoboken, N.J.)

Published: February 21, 2021

Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma.

Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma.

Journal: Leukemia & lymphoma

Published: August 28, 2020

Retrospective analysis of plasmacytoma in Kansai Myeloma Forum Registry.

Retrospective analysis of plasmacytoma in Kansai Myeloma Forum Registry.

Journal: International journal of hematology

Published: April 13, 2020

Retrospective multi-center study of Adolescent and Young Adult (AYA) Multiple Myeloma in Kansai Myeloma Forum registry.

Retrospective multi-center study of Adolescent and Young Adult (AYA) Multiple Myeloma in Kansai Myeloma Forum registry.

Journal: International journal of hematology

Published: March 05, 2020

Effect of allogeneic hematopoietic cell transplantation for patients with T-prolymphocytic leukemia: a retrospective study from the Adult Lymphoma Working Group of the Japan Society for hematopoietic cell transplantation.

Effect of allogeneic hematopoietic cell transplantation for patients with T-prolymphocytic leukemia: a retrospective study from the Adult Lymphoma Working Group of the Japan Society for hematopoietic cell transplantation.

Journal: Annals of hematology

Published: June 11, 2019

Showing 1-12 of 30

Last Updated: 09/26/2026